Canadian Liver Journal最新文献

Assessment of birth cohort screening of chronic hepatitis C in colorectal cancer screening patients in British Columbia 评估不列颠哥伦比亚省结直肠癌筛查患者出生队列慢性丙型肝炎筛查情况

Canadian Liver Journal Pub Date : 2024-02-15 DOI: 10.3138/canlivj-2023-0024

Rojin Kaviani, Frank Y Chou, Chenxi He, Vladimir Marquez

{"title":"Assessment of birth cohort screening of chronic hepatitis C in colorectal cancer screening patients in British Columbia","authors":"Rojin Kaviani, Frank Y Chou, Chenxi He, Vladimir Marquez","doi":"10.3138/canlivj-2023-0024","DOIUrl":"https://doi.org/10.3138/canlivj-2023-0024","url":null,"abstract":"Since 2018, British Columbia (BC) has recommended chronic hepatitis C (HCV) screening for those born between 1945 and 1964, with a provincial prevalence of 2.31%. Combining HCV and colorectal cancer (CRC) screening can facilitate specialist referrals and follow-up. We assessed HCV screening uptake among CRC screening patients following the release of BC’s birth cohort guidelines and examined the COVID-19 pandemic’s impact on HCV screening practices. A retrospective review was conducted on patients referred to Vancouver Coastal Health Authority’s CRC screening program. Two groups, Cohort A (October–December 2019) and Cohort B (December 2021), were studied to identify pandemic-related changes. Data on demographics, liver disease history, hepatitis B or HIV co-infection rates, and initial anti-hepatitis C and ribonucleic acid (RNA) testing dates were collected. Statistical analyses were performed with Stata 15.1. A total of 579 patients were referred for the CRC screening program, of whom 465 were born between 1945 and 1964 and were included in the study. Among the 348 patients in cohort A, 144 (41%, 95% CI 36%–47%) were screened for HCV infection. Of these, four (1.2%) were positive for anti-hepatitis C, and one patient had positive RNA levels. Similar proportions of screenings were observed in cohort B (47.8%, 95% CI 39%–57%). Of those with liver disease, 66% had been screened for HCV. Birth cohort screening for HCV has been underutilized in British Columbia. Combining HCV and CRC screening could provide a practical approach to linking patients to healthcare.","PeriodicalId":505573,"journal":{"name":"Canadian Liver Journal","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139774531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of birth cohort screening of chronic hepatitis C in colorectal cancer screening patients in British Columbia 评估不列颠哥伦比亚省结直肠癌筛查患者出生队列慢性丙型肝炎筛查情况

Canadian Liver Journal Pub Date : 2024-02-15 DOI: 10.3138/canlivj-2023-0024

Rojin Kaviani, Frank Y Chou, Chenxi He, Vladimir Marquez

{"title":"Assessment of birth cohort screening of chronic hepatitis C in colorectal cancer screening patients in British Columbia","authors":"Rojin Kaviani, Frank Y Chou, Chenxi He, Vladimir Marquez","doi":"10.3138/canlivj-2023-0024","DOIUrl":"https://doi.org/10.3138/canlivj-2023-0024","url":null,"abstract":"Since 2018, British Columbia (BC) has recommended chronic hepatitis C (HCV) screening for those born between 1945 and 1964, with a provincial prevalence of 2.31%. Combining HCV and colorectal cancer (CRC) screening can facilitate specialist referrals and follow-up. We assessed HCV screening uptake among CRC screening patients following the release of BC’s birth cohort guidelines and examined the COVID-19 pandemic’s impact on HCV screening practices. A retrospective review was conducted on patients referred to Vancouver Coastal Health Authority’s CRC screening program. Two groups, Cohort A (October–December 2019) and Cohort B (December 2021), were studied to identify pandemic-related changes. Data on demographics, liver disease history, hepatitis B or HIV co-infection rates, and initial anti-hepatitis C and ribonucleic acid (RNA) testing dates were collected. Statistical analyses were performed with Stata 15.1. A total of 579 patients were referred for the CRC screening program, of whom 465 were born between 1945 and 1964 and were included in the study. Among the 348 patients in cohort A, 144 (41%, 95% CI 36%–47%) were screened for HCV infection. Of these, four (1.2%) were positive for anti-hepatitis C, and one patient had positive RNA levels. Similar proportions of screenings were observed in cohort B (47.8%, 95% CI 39%–57%). Of those with liver disease, 66% had been screened for HCV. Birth cohort screening for HCV has been underutilized in British Columbia. Combining HCV and CRC screening could provide a practical approach to linking patients to healthcare.","PeriodicalId":505573,"journal":{"name":"Canadian Liver Journal","volume":"425 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139834257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of first-wave COVID-19 restrictions on HCV testing in Alberta, Canada: A trend analysis from 2019 to 2022 加拿大艾伯塔省第一波 COVID-19 限制对 HCV 检测的影响：2019 年至 2022 年趋势分析

Canadian Liver Journal Pub Date : 2024-02-05 DOI: 10.3138/canlivj-2023-0027

L. A. Thompson, S. Plitt, Ran Zhuo, Carmen L. Charlton

{"title":"The effect of first-wave COVID-19 restrictions on HCV testing in Alberta, Canada: A trend analysis from 2019 to 2022","authors":"L. A. Thompson, S. Plitt, Ran Zhuo, Carmen L. Charlton","doi":"10.3138/canlivj-2023-0027","DOIUrl":"https://doi.org/10.3138/canlivj-2023-0027","url":null,"abstract":"Prior to the COVID-19 pandemic, Alberta was on track to meet national HCV elimination targets by 2030. However, it is unclear how the pandemic has affected progress. Here, we aim to assess the impact of first-wave COVID-19 restrictions on Alberta HCV testing trends. HCV testing information was extracted from the provincial public health laboratory from 2019 to 2022. HCV antibody and RNA testing were categorized into: (1) number ordered, (2) number positive, and (3) percent positivity, and stratified by HCV history status. Testing trends were evaluated across locations engaging high-risk individuals and priority demographics. An interrupted time-series analysis was used to identify average monthly testing rates before, during, and after first-wave COVID-19 restrictions. Overall, HCV testing trends were significantly affected by COVID-19 restrictions in April 2020. Average monthly rates decreased by 98.39 antibody tests ordered per 100,000 among individuals without an HCV history and by 1.78 RNA tests ordered per 100,000 among those with an HCV history. While antibody and RNA testing trends started to rebound in the follow-up period relative to pre-restriction period, testing levels in the follow-up period remained below pre-restriction levels for all groups, except for addiction/recovery centers and emergency room/acute care facilities, which increased. If rates are to return to pre-restriction levels and elimination goals are to be met, more work is needed to engage individuals in HCV testing. As antibody testing rates are rebounding, reengaging those with a history of HCV for viral load monitoring and treatment should be prioritized.","PeriodicalId":505573,"journal":{"name":"Canadian Liver Journal","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139865152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of first-wave COVID-19 restrictions on HCV testing in Alberta, Canada: A trend analysis from 2019 to 2022 加拿大艾伯塔省第一波 COVID-19 限制对 HCV 检测的影响：2019 年至 2022 年趋势分析

Canadian Liver Journal Pub Date : 2024-02-05 DOI: 10.3138/canlivj-2023-0027

L. A. Thompson, S. Plitt, Ran Zhuo, Carmen L. Charlton

{"title":"The effect of first-wave COVID-19 restrictions on HCV testing in Alberta, Canada: A trend analysis from 2019 to 2022","authors":"L. A. Thompson, S. Plitt, Ran Zhuo, Carmen L. Charlton","doi":"10.3138/canlivj-2023-0027","DOIUrl":"https://doi.org/10.3138/canlivj-2023-0027","url":null,"abstract":"Prior to the COVID-19 pandemic, Alberta was on track to meet national HCV elimination targets by 2030. However, it is unclear how the pandemic has affected progress. Here, we aim to assess the impact of first-wave COVID-19 restrictions on Alberta HCV testing trends. HCV testing information was extracted from the provincial public health laboratory from 2019 to 2022. HCV antibody and RNA testing were categorized into: (1) number ordered, (2) number positive, and (3) percent positivity, and stratified by HCV history status. Testing trends were evaluated across locations engaging high-risk individuals and priority demographics. An interrupted time-series analysis was used to identify average monthly testing rates before, during, and after first-wave COVID-19 restrictions. Overall, HCV testing trends were significantly affected by COVID-19 restrictions in April 2020. Average monthly rates decreased by 98.39 antibody tests ordered per 100,000 among individuals without an HCV history and by 1.78 RNA tests ordered per 100,000 among those with an HCV history. While antibody and RNA testing trends started to rebound in the follow-up period relative to pre-restriction period, testing levels in the follow-up period remained below pre-restriction levels for all groups, except for addiction/recovery centers and emergency room/acute care facilities, which increased. If rates are to return to pre-restriction levels and elimination goals are to be met, more work is needed to engage individuals in HCV testing. As antibody testing rates are rebounding, reengaging those with a history of HCV for viral load monitoring and treatment should be prioritized.","PeriodicalId":505573,"journal":{"name":"Canadian Liver Journal","volume":"5 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139805347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunosuppression in two cases of indeterminate hepatitis 免疫抑制在两例不确定肝炎中的应用

Canadian Liver Journal Pub Date : 2024-02-01 DOI: 10.3138/canlivj-2023-0019

Alexandra Cohen, Fernando Alvarez

引用次数: 0